List view / Grid view

NASH

Filter the results

 

news

BMS Phase II study in non-alcoholic steatohepatitis a success 

24 April 2017 | By Niamh Marriott, Junior Editor

BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.

news

FDA grants fast track for Shire’s NASH investigational treatment

29 July 2016 | By Mandy Parrett, Editorial Assistant

Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.